Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Quest Diagnostics to Offer Newly Cleared Alzheimer's Blood Test

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at clpmag.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Quest Diagnostics will offer a recently FDA-cleared Roche blood test for Alzheimer's disease and launch a multi-biomarker laboratory-developed test to improve diagnostic accuracy using blood samples.

This Wire brief sits within Fusion42's coverage of Health, and 5 sources have reported it between 24 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

You can now access a scalable Alzheimer’s diagnostic tool that lowers reliance on costly scans. Health founders building blood biomarker tests should prioritise integration with clinical trial networks to capture early market opportunity.

◆ Coverage

5 sources · first reported 24 Aug 2026 · latest 25 Aug 2026

◆ Related on Wire

◆ Topics

Healthalzheimersblood-testFDA-cleareddiagnosticsbiomarkers